The EGM in ChronTech Pharma AB

The EGM in ChronTech Pharma AB on 7 January, 2011 resolved to authorize the Board to resolve new issue of shares,  warrants and/or convertible debentures and with or without preferential rights for the shareholders.

The EGM resolved a limit of USD 4 million with respect to issuance of shares to new investors that are not shareholders in the Company. The existing shareholders shall not later than 30 June, 2011 be offered to subscribe for new shares at the same terms as the new investors but limited to 50 per cent of the number of shares that is issued to new investors. In addition, if the shares are issued at a price below SEK 0.50, the subscribers in the recently completed rights issue shall be compensated in a manner the Board deems appropriate and within the frames of the Companies Act.

For more information, please contact:

Anders Vahlne, CEO and Head of Research, ChronTech Pharma AB

Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28,
E-mail: anders.vahlne@ki.se

About ChronTech

ChronTech develops the therapeutic DNA vaccines ChronVac-C® and ChronVac-B drugs against chronic hepatitis C virus and hepatitis B virus infections, i.e. chronic infections with jaundice causing viruses which can lead to liver cirrhosis and liver cancer. ChronTech has also developed and further develops a patent pending new type of injection needle for a more effective uptake of DNA vaccines. ChronTech also have part ownership in the wound healing therapy ChronSeal®, and in the new platform technology RAS®. The ChronTech share is admitted to trade on First North. Remium AB is Certified Adviser for ChronTech. For more information, please visit: www.chrontech.se

In the event of any discrepancy between the Swedish and English versions of this press release, the Swedish version will take precedence.